

Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atherosclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027

Market Report | 2022-10-12 | 205 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period. The growth in the cardiac marker testing market is majorly driven by the significant rising cases of cardiovascular diseases, rapid growth in older population, and increasing research & funding initiatives from public/private organizations to discover novel cardiac biomarkers with improved efficacy for diagnosing heart conditions. According to the American Heart Association (AHA), the prevalence of CVD in the US is projected to reach 40.5% of the total population by 2030, from 36.9% in 2010.

However, technical problems associated with sample collection and storage and issues related to regulatory and reimbursement systems are some of the factors expected to restrain market growth to a certain extent.

"Troponin I and T estimated held the largest share of cardiac marker testing market in 2021, by Biomarker Type "

Based on biomarker type, the cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide (BNP and Nt-proBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment accounted for the largest share of 51.1 % of the cardiac marker testing market in 2021. Factors such as high sensitivity and specificity, long elevation time (rises over 4-8 hours, peaks at 10-24 hours, and declines over ten days), and rapid prediction of outcomes are driving the growth of this segment. In addition, lab technicians are more familiar

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

with the use of these markers as compared to other biomarkers

"Laboratory testing facilities segment accounted for the largest share of the cardiac marker testing market in 2021, by End user ". Based on end users, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2021, the laboratory testing facilities segment accounted for the largest share of 61.4% of the global cardiac marker testing market. Factors such as high testing throughput, better sensitivity & diagnostic accuracy compared to POC testing, and high preference for laboratory testing over POCT testing are driving the growth of this segment.

"The Asia Pacific market to grow at the highest CAGR during the forecast period"

The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period. The Asia Pacific market is driven due rising growing investments by government agencies in emerging countries of Asia Pacific for the improvement of healthcare infrastructure, growing number of independent clinical laboratories, presence of large patient population, and strategies adopted by players to increase their cardiac testing product reach in Asia Pacific.

Breakdown of supply-side primary interviews:

- By Company Type: Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%
- By Designation: C-level: 10%, D-level: 14%, and Others: 76%
- By Region: North America: 40%, Europe: 32%, APAC: 20%, Latin America: 5%, and the Middle East & Africa: 3%

The major players operating in the cardiac marker testing market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), PerkinElmer, Inc. (US), bioMerieux SA (France), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), DiaSorin (Italy), and Tosoh Corporation (Japan), LSI Medience Corporation (Japan), Quidel Corporation (US), Randox Laboratories (UK), Guangzhou Wondfo Biotech Co., Ltd. (China), Boditech Med Inc. (South Korea), Tulip Diagnostics (P) Ltd (India), BTNX Inc. (Canada), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), CTK Biotech, Inc. (US), Creative Diagnostics (US), LifeSign LLC. (US), CardioGenics Holdings Inc (Canada), and Atlas Medical GmbH (Germany).

Research Coverage

This report studies the cardiac marker testing market based on the product, biomarker type, disease, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the cardiac marker testing market, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

Table of Contents:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1	INTRODUCTION	28
1.1	STUDY OBJECTIVES	28
1.2	MARKET DEFINITION	28
1.3	STUDY SCOPE	29
1.3.1	MARKETS COVERED	29
1.3.2	GEOGRAPHIC SCOPE	29
1.3.3	INCLUSIONS & EXCLUSIONS	30
1.3.4	YEARS CONSIDERED	30
1.4	CURRENCY CONSIDERED	30
1.5	LIMITATIONS	30
1.6	MARKET STAKEHOLDERS	31
1.7	SUMMARY OF CHANGES	31
2	RESEARCH METHODOLOGY	32
2.1	RESEARCH DATA	32
FIGURE 1	RESEARCH DESIGN	32
2.1.1	SECONDARY RESEARCH	33
2.1.2	PRIMARY RESEARCH	34
2.1.2.1	Key data from primary sources	34
FIGURE 2	BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	35
FIGURE 3	CARDIAC MARKER TESTING MARKET: BREAKDOWN OF PRIMARIES	35
2.2	MARKET SIZE ESTIMATION	35
FIGURE 4	RESEARCH METHODOLOGY: HYPOTHESIS BUILDING	36
2.2.1	REVENUE MAPPING-BASED MARKET ESTIMATION	36
2.2.2	MARKET ESTIMATION BASED ON END USERS	37
FIGURE 5	CARDIAC MARKER TESTING MARKET: MARKET SIZE ESTIMATION	37
2.2.3	PRIMARY RESEARCH VALIDATION	37
2.3	DATA TRIANGULATION	38
FIGURE 6	DATA TRIANGULATION METHODOLOGY	38
2.4	RESEARCH ASSUMPTIONS AND LIMITATIONS	39
2.4.1	RESEARCH ASSUMPTIONS	39
2.4.2	RESEARCH LIMITATIONS	39
3	EXECUTIVE SUMMARY	40
FIGURE 7	CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2022 VS. 2027 (USD MILLION)	40
FIGURE 8	CARDIAC MARKER TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)	41
FIGURE 9	GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET	42
4	PREMIUM INSIGHTS	43
4.1	CARDIAC MARKER TESTING MARKET OVERVIEW	43
FIGURE 10	RIISING INCIDENCE OF CARDIOVASCULAR DISEASES AND ONGOING CLINICAL TRIALS FOR NOVEL BIOMARKERS TO DRIVE MARKET	43
4.2	CARDIAC MARKER TESTING MARKET SHARE, BY PRODUCT, 2022 VS. 2027	43
FIGURE 11	REAGENTS & KITS TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD	43
4.3	EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER AND REGION	44
FIGURE 12	LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021	44
4.4	CARDIAC MARKER TESTING MARKET: GEOGRAPHICAL SNAPSHOT	44

FIGURE 13	CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD	44
5	MARKET OVERVIEW	45
5.1	INTRODUCTION	45
5.2	MARKET DYNAMICS	45
FIGURE 14	CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	45
5.2.1	DRIVERS	46
5.2.1.1	Rising incidence of cardiovascular diseases	46
5.2.1.2	Increasing geriatric population and subsequent rise in heart conditions worldwide	46
5.2.1.3	Growing research & funding initiatives from public & private organizations	47
5.2.1.4	Rising clinical studies for identification of novel cardiac biomarkers	47
5.2.2	RESTRAINTS	47
5.2.2.1	Technical issues related to sample collection & storage	47
5.2.2.2	Unfavorable regulatory processes and limited reimbursement structure	48
5.2.3	OPPORTUNITIES	48
5.2.3.1	Point-of-care testing with cardiac biomarkers	48
5.2.3.2	Ongoing research on novel cardiac biomarkers for cardiovascular diseases	49
5.2.3.3	Emerging markets offer high-growth opportunities	49
5.2.4	CHALLENGES	50
5.2.4.1	Challenges associated with biomarker assay validation	50
5.3	REGULATORY SCENARIO	50
TABLE 1	KEY REGULATORY BODIES & GOVERNMENT AGENCIES	50
5.3.1	KEY REGULATORY GUIDELINES	51
5.3.1.1	US	51
TABLE 2	US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES	51
FIGURE 15	US: REGULATORY PROCESS FOR IVD DEVICES	52
5.3.1.2	Canada	53
FIGURE 16	CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA	53
5.3.1.3	Europe	53
TABLE 3	EUROPE: CLASSIFICATION OF IVD DEVICES	53
FIGURE 17	EUROPE: REGULATORY PROCESS FOR IVD DEVICES	54
5.3.1.4	Japan	55
FIGURE 18	REGULATORY PROCESS FOR IVD DEVICES IN JAPAN	55
TABLE 4	JAPAN: CLASSIFICATION OF IVD REAGENTS	55
TABLE 5	JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	56
5.3.1.5	China	56
TABLE 6	CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	56
5.3.1.6	India	56
FIGURE 19	INDIA: REGULATORY PROCESS FOR IVD DEVICES	57
5.3.1.7	Russia	57
TABLE 7	RUSSIA: CLASSIFICATION OF IVD DEVICES	57
5.3.1.8	Mexico	58
FIGURE 20	MEXICO: REGULATORY PROCESS FOR IVD DEVICES	58
TABLE 8	MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	58
5.3.1.9	Brazil	59
FIGURE 21	BRAZIL: REGULATORY PROCESS FOR IVD DEVICES	59
5.3.1.10	South Korea	59
TABLE 9	SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	59

5.4	REIMBURSEMENT SCENARIO	60
TABLE 10	REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS	60
5.5	VALUE CHAIN ANALYSIS	61
FIGURE 22	CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS	61
5.6	SUPPLY CHAIN ANALYSIS	62
FIGURE 23	DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES	63
5.7	ECOSYSTEM ANALYSIS: PARENT MARKET (IN VITRO DIAGNOSTICS)	63
5.8	PRICING ANALYSIS	64
5.8.1	AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS BY KEY PLAYERS	64
TABLE 11	CARDIAC BIOMARKER TROPONIN I AND T TEST KITS	64
TABLE 12	CARDIAC BIOMARKER CK-MB TEST KITS	64
TABLE 13	CARDIAC BIOMARKER BPN OR NT-PROBNP TEST KITS	64
TABLE 14	CARDIAC BIOMARKER MYOGLOBIN TEST KITS	64
TABLE 15	CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS	65
TABLE 16	AVERAGE SELLING PRICE OF CARDIAC MARKET TEST KITS TREND, BY COUNTRY (USD)	65
5.9	PORTER'S FIVE FORCES ANALYSIS	65
TABLE 17	CARDIAC MARKER TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS	65
5.9.1	BARGAINING POWER OF BUYERS	66
5.9.2	BARGAINING POWER OF SUPPLIERS	66
5.9.3	THREAT OF NEW ENTRANTS	66
5.9.4	THREAT OF SUBSTITUTES	66
5.9.5	INTENSITY OF COMPETITIVE RIVALRY	66
5.10	PATENT ANALYSIS	67
FIGURE 24	TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING (JANUARY 2012-SEPTEMBER 2022)	67
FIGURE 25	TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING (JANUARY 2012-SEPTEMBER 2022)	67
5.11	KEY CONFERENCES & EVENTS (2022-2024)	68
TABLE 18	CARDIAC MARKER TESTING MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS	68
5.12	CASE STUDY	69
5.12.1	DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I	69
TABLE 19	CASE 1: DIAGNOSING LOWER LEVEL OF TROPONIN IN CARDIAC PATIENTS	69
5.13	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	69
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	70
5.14.1	KEY STAKEHOLDERS	70
FIGURE 26	INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR CARDIAC MARKER TESTING KITS AND INSTRUMENTS	70
TABLE 20	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%)	70
5.15	KEY BUYING CRITERIA BY END USERS	71
TABLE 21	KEY BUYING CRITERIA FOR PRODUCTS	71
6	CARDIAC MARKER TESTING MARKET, BY PRODUCT	72
6.1	INTRODUCTION	73
TABLE 22	CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	73
6.2	REAGENTS & KITS	73
6.2.1	RIISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND	73
TABLE 23	CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2020-2027 (USD MILLION)	74
TABLE 24	CARDIAC MARKER TESTING MARKET FOR REAGENTS & KITS, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	74
6.3	INSTRUMENTS	75
TABLE 25	CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY REGION, 2020-2027 (USD MILLION)	75
TABLE 26	CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION)	75

TABLE 27	CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	76
6.3.1	CHEMILUMINESCENCE	76
6.3.1.1	Most preferred method for quantification of cardiac biomarkers to drive segment growth	76
TABLE 28	CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY REGION, 2020-2027 (USD MILLION)	77
TABLE 29	CARDIAC MARKER TESTING MARKET FOR CHEMILUMINESCENCE, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	77
6.3.2	IMMUNOFLUORESCENCE	78
6.3.2.1	Demand for stable and safer reagents to support market growth	78
TABLE 30	CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2020-2027 (USD MILLION)	78
TABLE 31	CARDIAC MARKER TESTING MARKET FOR IMMUNOFLUORESCENCE, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	79
6.3.3	ELISA	79
6.3.3.1	Long shelf life and ease of use to propel segment growth	79
TABLE 32	CARDIAC MARKER TESTING MARKET FOR ELISA, BY REGION, 2020-2027 (USD MILLION)	79
TABLE 33	CARDIAC MARKER TESTING MARKET FOR ELISA, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	80
6.3.4	IMMUNOCHROMATOGRAPHY	80
6.3.4.1	Increasing use in point-of-care settings to drive adoption of this technique	80
TABLE 34	CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY REGION, 2020-2027 (USD MILLION)	81
TABLE 35	CARDIAC MARKER TESTING MARKET FOR IMMUNOCHROMATOGRAPHY, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	81
7	CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE	82
7.1	INTRODUCTION	83
TABLE 36	CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	83
7.2	TROPONIN I AND T	83
7.2.1	HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET	83
TABLE 37	CHARACTERISTICS OF TROPONIN CARDIAC MARKERS	84
TABLE 38	CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY REGION, 2020-2027 (USD MILLION)	84
TABLE 39	CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY DISEASE, 2020-2027 (USD MILLION)	85
TABLE 40	CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY END USER, 2020-2027 (USD MILLION)	85
7.3	CREATINE KINASE-MB (CK-MB)	85
7.3.1	DIAGNOSIS OF ACUTE MYOCARDIAL INJURY USING CK-MB TO DRIVE MARKET	85
TABLE 41	CHARACTERISTICS OF CK-MB CARDIAC MARKER	86
TABLE 42	CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY REGION, 2020-2027 (USD MILLION)	86
TABLE 43	CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY DISEASE, 2020-2027 (USD MILLION)	87
TABLE 44	CARDIAC MARKER TESTING MARKET FOR CREATINE KINASE-MB (CK-MB), BY END USER, 2020-2027 (USD MILLION)	87
7.4	NATRIURETIC PEPTIDE (BNP AND NT-PROBNP)	87
7.4.1	USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION	87
TABLE 45	CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2020-2027 (USD MILLION)	88
TABLE 46	CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY DISEASE, 2020-2027 (USD MILLION)	88
TABLE 47	CARDIAC MARKER TESTING MARKET FOR NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2020-2027 (USD MILLION)	89
7.5	MYOGLOBIN	89
7.5.1	RAPID INCREASE AND NORMALIZATION ASSOCIATED WITH MYOGLOBIN TO DRIVE MARKET	89
TABLE 48	CHARACTERISTICS OF MYOGLOBIN CARDIAC MARKERS	89
TABLE 49	CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2020-2027 (USD MILLION)	90
TABLE 50	CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY DISEASE, 2020-2027 (USD MILLION)	90

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 51	CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2020-2027 (USD MILLION)	91
7.6	HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP)	91
7.6.1	ABILITY OF HSCRP TESTS TO ACCURATELY MEASURE LOW LEVELS OF CRP TO SUPPORT MARKET GROWTH	91
TABLE 52	CUT-OFFS FOR CRP USING STANDARDIZED ASSAYS	91
TABLE 53	CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY REGION, 2020-2027 (USD MILLION)	92
TABLE 54	CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY DISEASE, 2020-2027 (USD MILLION)	92
TABLE 55	CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP), BY END USER, 2020-2027 (USD MILLION)	93
7.7	OTHER CARDIAC BIOMARKERS	93
TABLE 56	CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY REGION, 2020-2027 (USD MILLION)	94
TABLE 57	CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY DISEASE, 2020-2027 (USD MILLION)	94
TABLE 58	CARDIAC MARKER TESTING MARKET FOR OTHER CARDIAC BIOMARKERS, BY END USER, 2020-2027 (USD MILLION)	95
8	CARDIAC MARKER TESTING MARKET, BY DISEASE	96
8.1	INTRODUCTION	97
TABLE 59	CARDIAC MARKER TESTING MARKET, BY DISEASE, 2020-2027 (USD MILLION)	97
8.2	MYOCARDIAL INFARCTION	97
8.2.1	AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION OF MI TO DRIVE MARKET	97
TABLE 60	CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2020-2027 (USD MILLION)	98
?		
8.3	CONGESTIVE HEART FAILURE	98
8.3.1	INCREASING USE OF MULTI-MARKER TESTING TO SUPPORT MARKET GROWTH	98
TABLE 61	CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2020-2027 (USD MILLION)	99
8.4	ACUTE CORONARY SYNDROME	99
8.4.1	INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS	99
TABLE 62	CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2020-2027 (USD MILLION)	100
8.5	ATHEROSCLEROSIS	100
8.5.1	HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE UPTAKE OF CARDIAC MARKERS	100
TABLE 63	CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2020-2027 (USD MILLION)	101
8.6	ISCHEMIA	101
8.6.1	MULTIPLE COMPLICATIONS CAUSED BY ISCHEMIA TO DRIVE ADOPTION OF DIAGNOSTIC TESTS	101
TABLE 64	CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2020-2027 (USD MILLION)	101
9	CARDIAC MARKER TESTING MARKET, BY END USER	102
9.1	INTRODUCTION	103
TABLE 65	CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)	103
9.2	LABORATORY TESTING FACILITIES	103
TABLE 66	CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2020-2027 (USD MILLION)	104
TABLE 67	CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2020-2027 (USD MILLION)	104
9.2.1	HOSPITAL LABORATORIES	104
9.2.1.1	Emergency patient care and early diagnosis associated with in-house labs to drive market	104
TABLE 68	CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020-2027 (USD MILLION)	105
9.2.2	REFERENCE LABORATORIES	105
9.2.2.1	Affordable and time-efficient services associated with reference laboratories to support market growth	105
TABLE 69	CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020-2027 (USD MILLION)	105
9.2.3	CONTRACT TESTING LABORATORIES	106
9.2.3.1	Ability to perform multiple tests and cover wider matrices to support market growth	106

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 70	CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2020-2027 (USD MILLION)	106
9.3	ACADEMIC INSTITUTES	106
9.3.1	CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET	106
TABLE 71	CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2020-2027 (USD MILLION)	107
9.4	POINT-OF-CARE TESTING FACILITIES	107
9.4.1	EARLY DETECTION AND LOWER TURNAROUND TIME TO DRIVE MARKET	107
TABLE 72	CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2020-2027 (USD MILLION)	108
10	CARDIAC MARKER TESTING MARKET, BY REGION	109
10.1	INTRODUCTION	110
TABLE 73	CARDIAC MARKER TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)	110
10.2	NORTH AMERICA	110
FIGURE 27	NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT	111
TABLE 74	NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	111
TABLE 75	NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	112
TABLE 76	NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	112
TABLE 77	NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION)	113
TABLE 78	NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)	113
10.2.1	US	113
10.2.1.1	Growing support from NIH for development of novel cardiac biomarkers to drive market	113
TABLE 79	US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	114
10.2.2	CANADA	114
10.2.2.1	Increasing government initiatives supporting cardiac marker testing to boost market growth	114
TABLE 80	CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	115
10.3	EUROPE	115
TABLE 81	EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	115
TABLE 82	EUROPE CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	116
TABLE 83	EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	116
TABLE 84	EUROPE: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION)	116
TABLE 85	EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)	117
10.3.1	GERMANY	117
10.3.1.1	Higher healthcare expenditure to drive demand for diagnostic tests	117
TABLE 86	GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	117
10.3.2	UK	118
10.3.2.1	Government initiatives to expand diagnostic facilities to boost adoption of cardiac biomarkers	118
TABLE 87	UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	118
10.3.3	FRANCE	118
10.3.3.1	Rising demand for early CVD diagnosis to drive market	118
TABLE 88	FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	119
10.3.4	ITALY	119
10.3.4.1	Adoption of advanced diagnostic technologies to drive market	119
TABLE 89	ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	119
10.3.5	SPAIN	120
10.3.5.1	Establishment of large and advanced laboratories to drive uptake of cardiac marker testing	120
TABLE 90	SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	120

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.3.6 REST OF EUROPE (ROE) 120

TABLE 91 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 121

10.4 ASIA PACIFIC 121

FIGURE 28 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 122

TABLE 92 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 123

TABLE 93 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) 123

TABLE 94 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 124

TABLE 95 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION) 124

TABLE 96 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION) 124

10.4.1 JAPAN 125

10.4.1.1 Presence of established healthcare system with advanced laboratory facilities to drive market 125

TABLE 97 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 125

10.4.2 CHINA 125

10.4.2.1 Increasing number of independent clinical laboratories to drive demand for cardiac markers 125

TABLE 98 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 126

10.4.3 INDIA 126

10.4.3.1 Presence of large patient population to drive demand for cardiac marker testing 126

TABLE 99 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 127

10.4.4 SOUTH KOREA 127

10.4.4.1 Growing number of private hospitals to drive adoption of advanced testing services 127

TABLE 100 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 127

10.4.5 AUSTRALIA 128

10.4.5.1 High healthcare expenditure to support market growth 128

TABLE 101 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 128

10.4.6 REST OF ASIA PACIFIC (ROAPAC) 128

TABLE 102 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 128

10.5 LATIN AMERICA 129

TABLE 103 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 129

TABLE 104 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION) 130

TABLE 105 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 130

TABLE 106 LATIN AMERICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION) 130

TABLE 107 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION) 131

10.5.1 BRAZIL 131

10.5.1.1 Rising government support for advancements in healthcare to support market growth 131

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 108	BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	131
10.5.2	MEXICO	132
10.5.2.1	Rising demand for technologically advanced products to drive uptake for cardiac markers	132
TABLE 109	MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	132
10.5.3	REST OF LATIN AMERICA (ROLATAM)	132
TABLE 110	REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	133
10.6	MIDDLE EAST & AFRICA	133
10.6.1	RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS	133
TABLE 111	MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020-2027 (USD MILLION)	133
TABLE 112	MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	134
TABLE 113	MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET FOR INSTRUMENTS, BY TECHNOLOGY, 2020-2027 (USD MILLION)	134
TABLE 114	MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2020-2027 (USD MILLION)	134
11	COMPETITIVE LANDSCAPE	135
11.1	OVERVIEW	135
11.2	STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN	135
FIGURE 29	OVERVIEW OF STRATEGIES ADOPTED BY COMPANIES (2019?2022)	136
11.3	REVENUE ANALYSIS	137
FIGURE 30	REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2018?2021)	137
11.4	CARDIAC MARKER TESTING MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)	137
FIGURE 31	CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER (2021)	138
TABLE 115	CARDIAC MARKER TESTING MARKET: DEGREE OF COMPETITION	138
11.5	COMPANY EVALUATION QUADRANT FOR MAJOR PLAYERS (AS OF 2021)	139
11.5.1	STARS	139
11.5.2	EMERGING LEADERS	139
11.5.3	PERVASIVE PLAYERS	139
11.5.4	PARTICIPANTS	140
FIGURE 32	CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION QUADRANT (2021)	140
11.6	COMPANY EVALUATION QUADRANT (SMES/STARTUPS)	141
11.6.1	PROGRESSIVE COMPANIES	141
11.6.2	RESPONSIVE COMPANIES	141
11.6.3	DYNAMIC COMPANIES	141
11.6.4	STARTING BLOCKS	141
FIGURE 33	CARDIAC MARKER TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/STARTUPS)	142
11.7	COMPETITIVE BENCHMARKING	143
TABLE 116	OVERALL FOOTPRINT ANALYSIS	143
TABLE 117	PRODUCT FOOTPRINT ANALYSIS	144
TABLE 118	REGIONAL FOOTPRINT ANALYSIS	145
11.8	COMPETITIVE SCENARIO (2019-2022)	146
11.8.1	PRODUCT LAUNCHES & APPROVALS	146
11.8.2	DEALS	147
11.8.3	OTHER DEVELOPMENTS	147
?		

12 COMPANY PROFILES 148

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

12.1 KEY PLAYERS 148

12.1.1 F. HOFFMANN-LA ROCHE AG 148

TABLE 119 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 148

FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 149

12.1.2 ABBOTT LABORATORIES 152

TABLE 120 ABBOTT LABORATORIES: BUSINESS OVERVIEW 152

FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 153

12.1.3 SIEMENS HEALTHINEERS AG 156

TABLE 121 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 156

FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 157

12.1.4 DANAHER CORPORATION 160

TABLE 122 DANAHER CORPORATION: BUSINESS OVERVIEW 160

FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 161

12.1.5 BIOMERIEUX SA 163

TABLE 123 BIOMERIEUX SA: BUSINESS OVERVIEW 163

FIGURE 38 BIOMERIEUX SA: COMPANY SNAPSHOT (2021) 164

12.1.6 BECTON, DICKINSON AND COMPANY (BD) 165

TABLE 124 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 165

FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 166

12.1.7 BIO-RAD LABORATORIES, INC. 168

TABLE 125 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 168

FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 169

12.1.8 THERMO FISHER SCIENTIFIC INC. 171

TABLE 126 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 171

FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 172

12.1.9 DIASORIN 174

TABLE 127 DIASORIN: BUSINESS OVERVIEW 174

FIGURE 42 DIASORIN: COMPANY SNAPSHOT (2021) 175

12.1.10 PERKINELMER, INC. 177

TABLE 128 PERKINELMER INC: BUSINESS OVERVIEW 177

FIGURE 43 PERKINELMER INC: COMPANY SNAPSHOT (2021) 178

12.1.11 TOSOH CORPORATION 180

TABLE 129 TOSOH CORPORATION: BUSINESS OVERVIEW 180

FIGURE 44 TOSOH CORPORATION: COMPANY SNAPSHOT (2022) 181

12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) 184

TABLE 130 LSI MEDIENCE CORPORATION: BUSINESS OVERVIEW 184

FIGURE 45 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 184

12.1.13 QUIDEL CORPORATION 186

TABLE 131 QUIDEL CORPORATION: BUSINESS OVERVIEW 186

FIGURE 46 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 186

12.1.14 RANDOX LABORATORIES 188

TABLE 132 RANDOX LABORATORIES: BUSINESS OVERVIEW 188

12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD. 190

TABLE 133 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW 190

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.1.16	BODITECH MED INC.	192
TABLE 134	BODITECH MED INC: BUSINESS OVERVIEW	192
12.1.17	TULIP (P) DIAGNOSTICS LTD	194
TABLE 135	TULIP (P) DIAGNOSTICS LTD: BUSINESS OVERVIEW	194
12.1.18	BTNX INC.	195
TABLE 136	BTNX INC.: BUSINESS OVERVIEW	195
12.1.19	RESPONSE BIOMEDICAL	196
TABLE 137	RESPONSE BIOMEDICAL: BUSINESS OVERVIEW	196
12.1.20	ALFA SCIENTIFIC DESIGNS, INC.	198
TABLE 138	ALFA SCIENTIFIC DESIGNS, INC: BUSINESS OVERVIEW	198
12.2	OTHER PLAYERS	199
12.2.1	CTK BIOTECH, INC.	199
12.2.2	CREATIVE DIAGNOSTICS	199
12.2.3	LIFESIGN LLC.	200
12.2.4	CARDIOGENICS HOLDINGS INC	200
12.2.5	ATLAS MEDICAL GMBH	201
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.		
13	APPENDIX	202
13.1	DISCUSSION GUIDE	202
13.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	206
13.3	CUSTOMIZATION OPTIONS	208
13.4	RELATED REPORTS	209
13.5	AUTHOR DETAILS	210

Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atherosclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027

Market Report | 2022-10-12 | 205 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-06-23
		Signature	<div></div>